Search results
Author(s):
Harold Bays
Added:
1 year ago
ACC.23/WCC — Dr Harold Bays, Science Officer for the Obesity Medicine Association, member of the Board of Trustees of the Obesity Medicine Association, and member of the Board of Directors of the American Society of Preventive Cardiology joins us to talk about obesity management and the emergence of anti-obesity drugs and multidisciplinary team approach.
Discussion Points:
Unmet Needs in the…
View more
Lee Kaplan
Job title: Director of the Obesity, Metabolism & Nutrition Institute
Author
Liesbeth van Rossum
Job title: Professor, Obesity and Stress Hormone Research
Author
Susie Birney
Job title: Advocate for Obesity; EPCO Secretary
Author
Author(s):
Harold Bays
,
Naveed Sattar
Start date:
Jun 11, 2025
Harold Bays
Research Area(s) / Expertise:
Job title: Medical Director and President
Author
Lydia Alexander
Job title: Chief Medical Officer
Author
Author(s):
Harriette Van Spall
,
Milton Packer
Added:
2 months ago
AHA Conference 2024 — New insights into the SUMMIT trial, investigating tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Milton Packer (Baylor Heart and Vascular Institute, US) to discuss the findings from the randomized, double-blind, phase 3 SUMMIT trial (NCT04847557) investigating…
View more
AOM 2024
Author(s):
Harold Bays
,
Naveed Sattar
,
Mikhail Kosiborod
,
et al
Start date:
Jun 12, 2024
Broadcast
Author(s):
Harriette Van Spall
,
Mikhail Kosiborod
Added:
1 year ago
ESC 2023 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF trial (NCT04788511).
Around half of patients with heart failure have heart failure with preserved ejection fraction (HFpEF), and most patients with HFpEF are overweight or obese. Patients with…
View more